On January 20, 2020, the first case of COVID-19 emerged in the United States. More than 30 months on, the pandemic is still considered ongoing.
COVID-19, whose official name is coronavirus disease 2019, is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus). The COVID-19 pandemics continuation and severity are mainly due to the viruss fast mutations and its many variants. As a type of RNA virus, SARS-CoV-2 has a very high mutation rate. This is because the RNA polymerase that replicates the viruss genes doesnt have excellent proofreading skills. However, this actually helps the virus by allowing its variants to find new hosts and escape immunity induced by vaccination or previous in
fection. As a result, during the spreading of the virus, different geographic areas have generated genetically distinct variants.
In June 2021, the World Health Organization (WHO) started using the Greek alphabet to describe variants of interest, which are SARS-CoV-2 virus strains that are considered more dangerous than earlier forms of the virus. These variants are typically considered important due to their increased transmissibility, increased virulence, or the COVID-19 vaccines reduced effectiveness against them.
Prior to the WHO rolling out these rules, researchers around the globe came up with their own lineage naming rules to facilitate their genome sequencing of the virus. As SARS-CoV-2 is a rapidly evolving virus with a high rate of lineage turnover, some Western scientists used the letter A to denote the ancestral type, which is the Wuhan original strain, and the letter B to denote a derived lineage. Many variants of interest, such as alpha, beta, delta, and omicron, belong to lineage B.
The current variants of concern, or more precisely, subvariants (i.e. subsidiary variants) of concern, are BA.4 and BA.5. As of August 13, 2022, BA.5 cases accounted for 88.8 percent of all COVID-19 cases in the United States, followed by BA.4 (5.3 percent) and the latters own newer version BA4.6 (5.1 percent). From the statistics, we can see that BA.5 is more transmissible than BA.4, but so far, scientists havent gained an understanding as to why this is the case, as both subvariants are very similar.
As BA.4 and BA.5 are derived from BA.2, theyre very similar to the latter. According to a preprint study on MedRxiv, the spike proteins of BA.4 and BA.5 are identical, and comparable to BA.2. However, each of these subvariants has its own different mutations from BA.2 in other areas of the virus.
BA.4 and BA.5 are more contagious than any other subvariants of the SARS-CoV-
2 virus. According to a Japanese study, the Re value of BA.4 and BA.5 is 1.2 times higher than that of BA.2. The Re value, also known as the Rt value, is a viruss effective reproduction number, which represents the number of people in a population that can be infected by an individual at any specific time. This number represents a viruss transmissibility. BA.4 and BA.5 are 18.3 times more infectious than BA.2, and are currently the subvariants with the fastest increasing transmission rate.
BA.2 used to be the dominant subvariant around the globe, and BA.4 and BA.5 have rapidly replaced BA.2 in many countries, including the United States, since April 2022.
Furthermore, BA.4 and BA.5 appear to have higher pathogenicity than BA.2.
In a preprinted study of animal models, some Japanese researchers infected some wild-type Syrian hamsters with 105plaque-forming units of BA.4, BA.5, or BA.2 subvariants and performed histopathological analysis. They discovered that inflammation, hemorrhage, congestion, and alveolar damage were significantly higher in the lungs of BA.4 and BA.5-infected hamsters than in BA.2-infected ones. Therefore, BA.4 and BA.5 are more pathogenic than BA.2.
So far, the symptoms of BA.4 and BA.5 appear to be mostly upper-respiratory, including sore throat, running nose, incessant cough, headache, and fatigue, which are similar to the typical Omicron symptoms.
In comparison with the other subvariants, BA.4 and BA.5 are masters at bypassing immunity from a previous infection or vaccination. So people who were formerly infected by other Omicron subvariants can also get re-infected.
As the existing COVID-19 vaccines have been developed based on the original strain. Their protection against Omicron has been significantly reduced, and their protection against BA.4 and BA.5 may be even lower.
In the preprinted Japanese study, by analyzing peripheral blood sera from some convalescents, the researchers discovered that the serum neutralizing antibody titers with BA.4 and BA.5 in those patients who had had two to three doses of COVID-19 vaccines and later had a breakthrough infection by BA.1, were significantly lower than those with BA.2. That is, the combination of full-course vaccination and breakthrough infection cannot protect people from BA.4 or BA.5 infection.
Back on June 30, 2022, the Food and Drug Administration (FDA) warned that the effectiveness of existing COVID-19 vaccines had started to wane against Omicron variants, including BA.4/5. According to the FDAs statement, post-authorization observational studies have shown that effectiveness of primary vaccination wanes over time against certain variants, including Omicron.
Is the immunity gained from a previous COVID-19 natural infection effective against BA.4/5? The answer is: it depends. Although BA.4 and BA.5 subvariants are highly immune-evasive, the immunity acquired from an Omicron infection can still be helpful in protecting people against them. However, if the infection was by a different strain, then the protection offered by the infection-induced immunity may not be great.
The following studies shed some light on this issue.
According to the latest data from the UK Health Security Agency, similar to the pandemic situation in the United States, BA.5 has become the dominant subvariant in the UK, accounting for almost 80 percent of all COVID-19 cases.
The UK Health Security Agency has been carrying out a systematic cohort study (pdf) called the SARS-CoV-2 Immunity and Reinfection EvaluatioN (SIREN).
The participants of this study are more than 44,000 National Health Service healthcare workers from 135 hospitals across the UK. These participants are under active follow-up and undergo asymptomatic SARS-CoV-2 PCR testing every 2 weeks. The cohort had a high seropositivity rate of 30 percent before the second wave hit and is now over 95 percent vaccinated.
The incidence of new infections and reinfections is evaluated in this cohort. Reinfection is defined as a new infection (i.e. PCR positive) 90 days after a prior one.
The graph shows the fortnightly trends of PCR positivity in the SIREN cohort study, and they appear to be consistent with the trends of the alpha, delta, BA.1, BA.2, and other COVID variants. Starting from mid-May 2022, due to the prevalence of BA.4/BA.5, the trend has been going upwards again.
According to the graph, there has been an increase in both primary infection and reinfection rates since May 2022. The increase in primary infection rates indicates that Omicron and its subvariants have significantly enhanced transmission rates, resulting in a large number of infections. The increase in reinfection rates indicates that people who were previously infected can still get infected right now. Therefore, the immunity from natural infection doesnt necessarily offer protection against BA.4 and BA.5. Infection-induced immunitys effectiveness in preventing BA.4/5 infection depends on the strain of the previous infection.
Another preprint study was conducted by a team of researchers from Weill Cornell Medicine-Qatar in Doha. According to the study, young and middle-aged adults who were previously infected with earlier subvariants of Omicron may have substantial protection against BA.4 and BA.5. However, for the people that were infected with a variant that appeared before Omicron, they would not have similar protection against reinfection with BA.4 or BA.5.
This preprint study used the S-gene target failure (SGTF) infections to estimate the effectiveness of previous infections with SARS-CoV-2 in preventing reinfection with Omicron BA.4/BA.5 subvariants. The SGTF status provides a proxy for BA.4/BA.5 infections.
It was discovered that infection with a pre-Omicron variant prevented reinfection by BA.4 or BA.5 with an effectiveness rate of 28.3 percent, and prevented symptomatic reinfection with an effectiveness rate of 15.1 percent. This is because first, a long time has passed since the prior infection; and second, the virus has mutated a lot since then.
The study also found that a previous Omicron infection prevented reinfection by BA.4 or BA.5 with an effectiveness rate of 79.7 percent, and prevented symptomatic reinfection with an effectiveness rate of 76.1 percent. This is because first, the previous infection is relatively recent; and second, the viral mutations have not been large.
Therefore, regardless of previous COVID-19 infections, it is wise for us to maximize our own anti-viral immunity.
The BA.4 and BA.5 sub-lineages are the most transmissible and immune-evasive strains of the COVID-19 virus to date.What are the differences between them and the other subvariants that have given them their ability to escape immunity?
As aforementioned, BA.4 and BA.5 subvariants have identical spike sequences. In comparison with the BA.1 and BA.2 sub-lineages, they have L452R and F486V mutations and the R493Q reversion in the spike receptor binding domain (RBD), which is likely most targeted by neutralizing antibodies.
The production of neutralizing antibodies can be triggered by infection or vaccination. They can result in lifelong immunity to certain viruses. A neutralizing antibody can stop a pathogen from infecting the body by preventing the molecules on the pathogens surface from entering the human cells. As in the case of all enveloped viruses (i.e. the virus cells are inside a lipid membrane), neutralizing antibodies block the attachment of a SARS-CoV-2 virus to the cell and its entry into the cell to infect it.
Some viruses are able to evade neutralizing antibodies by having regular mutations. As a result, the antibodies can no longer recognize them. The BA.2, BA.4, and BA. 5 subvariants all carry a mutation in amino acid L452 of their spike protein. These L452 mutations facilitate their escape from some antibodies directed to certain regions of the receptor-binding domain, and such mutations have also caused several subvariants to appear.
The F486V mutations found in BA.4/5 also facilitate their escape from certain antibodies, whereas the R493Q reversion mutation restores receptor affinity (i.e. strength of the binding) and the fitness of BA.4/5. The Omicron lineage of SARS-CoV-2 continues to evolve, successively generating more subvariants that are not only more transmissible but also more evasive to antibodies.
According to Christian Althaus, a computational epidemiologist at the University of Bern, their capacity to infect people who were immune to earlier forms of COVID-19 strains has given rise to the prevalence of the BA.4 and BA.5 substrains.
The COVID-19 pandemic is entering its fourth year. People around the globe are hoping to see the light at the end of the tunnel. Then, will BA.4 and BA.5 subvariants be the last of their kind?
The answer is: no. Its almost certain that the virus will continue to mutate and persist.
According to Eric Topol, professor of molecular medicine at the Scripps Research Institute in California, We know BA.5 is not where this ends, unfortunately. We have further variants to work through for an indeterminate period of time.
Kei Sato, a virologist at the University of Tokyo, also holds the same view. He says, Nobody can say BA.4/5 is the final variant. It is highly probable that additional Omicron variants will emerge.
Already, a new variant, BA.2.75, has emerged and is spreading rapidly in India. Many medical experts believe that its another super-contagious Omicron mutant, and virologists fear that it will fuel a new wave of cases around the world.It has been given the nickname Centaurus by social media users.
So far, BA.2.75 has been detected in over 20 countries, with India being hit the hardest. According to the Indian authorities statistics, BA.2.75 is now behind two thirds of the new COVID-19 cases in India. However, it hasnt dramatically increased the countrys COVID-related hospitalization or death rate.
As the BA.2.75 subvariant is still evolving, it may develop more immune-evading mutations in the coming weeks. Some BA.2.75 sequences also have L452R mutations, which enhance the subvariants ability to re-infect people.
Link:
Will Omicron BA.5 Be the Last of the COVID Variants? - The Epoch Times
- Exercise promotes a molecular profile in muscle: Research - January 21st, 2023
- Molecular Diagnostics Laboratory < Laboratory Medicine - January 4th, 2023
- Molecular cloning - Wikipedia - December 18th, 2022
- Trends in Molecular Medicine | Journal - ScienceDirect - December 10th, 2022
- Researchers from Insilico Medicine, University of Copenhagen, and University of Chicago unravel molecular secrets hidden in premature aging diseases... - December 2nd, 2022
- Nuclear Medicine and Molecular Imaging Week: October 2-8, 2022 - October 29th, 2022
- Biochemistry & Molecular Biology | Medicine - October 29th, 2022
- Cellular and Molecular Medicine | Faculty of Medicine - October 21st, 2022
- Molecular Diagnostics > Fact Sheets > Yale Medicine - October 21st, 2022
- Expert Reviews in Molecular Medicine | Cambridge Core - October 13th, 2022
- UT Southwestern ranked top health care institution globally for published research by Nature Index - UT Southwestern - October 13th, 2022
- Common Antibiotics Are Losing Their Potency. Researchers Pinpoint Mechanism to Restore It. - NYU Langone Health - October 13th, 2022
- expert reaction to study looking at integrating human stem cell-derived brain-like tissue in the brains of newborn rats - Science Media Centre - October 13th, 2022
- HTG Provides Update on Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery - Yahoo Finance - October 13th, 2022
- UVA Discovers Key Driver of High Blood Pressure - UVA Health Newsroom - October 13th, 2022
- Postdoctoral Fellow in Lung Cancer Genomics job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 311727 - Times Higher Education - October 13th, 2022
- Common cold may increase the risk of long Covid - Earth.com - October 13th, 2022
- Caris' Precision Oncology Alliance Welcomes The Cancer Institute at The University of Tennessee Medical Center - PR Newswire - October 13th, 2022
- Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics - Yahoo... - October 13th, 2022
- Molecular Test Could Improve Early Detection of Pancreatic Cancer - Technology Networks - October 13th, 2022
- UTSW researchers identify key player in cellular response to stress - EurekAlert - October 4th, 2022
- New Antibody Demonstrates Therapeutic Benefits Against Alzheimers - SciTechDaily - October 4th, 2022
- Mount Sinai study uncovers mechanisms of reactive oxygen species in stem cell function and inflammation prevention - EurekAlert - October 4th, 2022
- NovoPath Pushes the Limits of Laboratory Information Systems with Integrated Workflows for Genetic and Molecular Testing - PR Newswire - October 4th, 2022
- Postdoctoral Fellow in Bioinformatics job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 311073 - Times Higher Education - October 4th, 2022
- Breast Cancer Awareness | Nick Jacobs | An unlikely partnership: The United States Army Space and Missile Defense Command and the Joyce Murtha Breast... - October 4th, 2022
- Tackling resistance to HIF2 drugs with an RNA-based therapy - UT Southwestern - October 4th, 2022
- OncoNano Medicine Announces Positive Phase 2 Data for Pegsitacianine as an adjunct to Cytoreductive Surgery of Peritoneal Carcinomatosis - Business... - October 4th, 2022
- SIMATS organizes Induction Ceremony - Afternoonnews - Afternoon News - October 4th, 2022
- ExPath Grad Student Madeline Mayday Awarded Grant from the NIDDK Cooperative Centers of Excellence in Hematology - Yale School of Medicine - September 25th, 2022
- Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes - Business Wire - September 25th, 2022
- New Startups Built From UC Davis Innovations Drive Solutions in Food, Health and Agriculture - University of California, Davis - September 25th, 2022
- Scientists Discover New Cancer Treatment - The Morning News - September 25th, 2022
- Rewriting the Textbook for Precision Medicine - Technology Networks - September 25th, 2022
- Biden says 'The pandemic is over,' but health experts disagree - Chief Healthcare Executive - September 25th, 2022
- Discovery Illuminates How Parkinson's Disease Spreads in The Brain - Weill Cornell Medicine Newsroom - September 25th, 2022
- AI Used to Determine Cause of Alzheimer's and Related Disorders - Inside Precision Medicine - September 25th, 2022
- Looking Ahead in the Treatment of Breast Cancer - Targeted Oncology - September 25th, 2022
- Researchers identify potential biomarker to distinguish two aggressive types of brain tumors in children - EurekAlert - September 25th, 2022
- New study reveals breakthrough infections increase immunity to COVID-19 - OHSU News - September 25th, 2022
- Coronavirus Today: Who's dying of COVID-19 now? - Los Angeles Times - September 25th, 2022
- Hoag Named Radiopharmaceutical Therapy Center of Excellence, Publishes Results of Breast and Prostate Cancer Trials - PR Newswire - September 8th, 2022
- Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines - Yahoo Finance - September 8th, 2022
- Scientists urged the Biden administration to launch an Operation Warp Speed to develop inhaled COVID vaccines. China beat the U.S. to the punch -... - September 8th, 2022
- Foundation Medicine to Share 14 Abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress Demonstrating the Power of Genomic... - September 8th, 2022
- Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader Phase... - September 8th, 2022
- Biden administration says the once-a-year shot phase of the COVID-19 pandemic has arrived - The Boston Globe - September 8th, 2022
- ICCBS welcomes students of MPhil and PhD Programs 2022 - The Academia Mag - September 8th, 2022
- Exciting PhD positions at the European Molecular Biology Laboratory (EMBL) job with EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) | 308114 - Times... - September 8th, 2022
- Congratulations to our NRF award winners | UCT News - University of Cape Town News - September 8th, 2022
- Patients with some forms of aggressive esophageal cancers may benefit from treatment targeting how cells self-regulate - EurekAlert - September 8th, 2022
- Molecular Medicine (M.Sc.) - Georg-August-Universitt Gttingen - August 30th, 2022
- Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated... - August 30th, 2022
- Feinstein Institutes Get $3M From Lupus Research Alliance to Study Remission and Future Therapies - Business Wire - August 30th, 2022
- Unlocking the Power of Precision Medicine the Rheumatology Example - Technology Networks - August 30th, 2022
- When to trust your covid test results and when to question them | Mint - Mint - August 30th, 2022
- Molecular Diagnostics Market Report 2022-2030: Increasing Adoption of Point-Of-Care (Poc) Testing and the Development of Novel Assays Presents... - August 30th, 2022
- Advancing Precision Oncology, Ochsner Health First to Fully Integrate with Tempus and Epic's Genomics Module - Newswise - August 30th, 2022
- Tiny, Touch-Based Sensor Could Help Patients Stay on Top of Their Medications - SciTechDaily - August 30th, 2022
- Stellar Scholars Join CLAS Faculty - UConn Today - University of Connecticut - August 30th, 2022
- COVID-19 gave new urgency to the science of restoring smell - Science News Magazine - August 30th, 2022
- Dr. Sun lab wins R01 from National Institutes of Health to study liver proteins - Wayne State University - August 22nd, 2022
- Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference - GlobeNewswire - August 22nd, 2022
- New Study Identifies How A Group Of Genes Are Linked To Behavioral Conditions - Forbes - August 22nd, 2022
- New gene variant that protects against coronary heart disease uncovered - EurekAlert - August 22nd, 2022
- How a Japanese Herbal Medicine Protects the Gut Against Inflammatory Bowel Disease - Neuroscience News - August 22nd, 2022
- Insilico Medicine presents on AI for drug discovery at 9th Annual Aging Research and Drug Discovery Conference - EurekAlert - August 22nd, 2022
- Why polio is back on the radar of Canadian health officials - Brighter World - August 22nd, 2022
- Angela DeMichele, MD, MSCE, Assesses the Value of I-SPY2 for Neoadjuvant Treatment of Early Breast Cancer - Cancer Network - August 22nd, 2022
- Exciting PhD positions at the European Molecular Biology Laboratory (EMBL) job with EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) | 304753 - Times... - August 22nd, 2022
- Sensor could help patients stay on top of their meds - EurekAlert - August 22nd, 2022
- Trivitron Healthcare launches CoE in metabolomics, genomics, newborn screening and molecular diagnostics - Express Healthcare - August 22nd, 2022
- Research Trends of Moxibustion Therapy for Pain Treatment Over the Pas | JPR - Dove Medical Press - August 22nd, 2022
- Edited Transcript of EXAI.OQ earnings conference call or presentation 18-Aug-22 12:30pm GMT - Yahoo Finance - August 22nd, 2022
- Roche launches COVID-19 test that detects and differentiates the emerging variant of interest BA.2.75 - PR Newswire - August 22nd, 2022
- Many Paths to Failure | Harvard Medical School - Harvard Medical School - August 5th, 2022
- Mitochondrial DNA Mutations Linked to Heart Disease Risk - University of California San Diego - August 5th, 2022
- UC Davis Sets a New Record, Surpasses $1 Billion in Research Funding - University of California, Davis - August 5th, 2022
- A first update on mapping the human genetic architecture of COVID-19 - Nature.com - August 5th, 2022
- Summer Scholars leave Duke with a once-in-a-lifetime research experience - Duke University - August 5th, 2022